---
title: "Trulieve Cannabis climbs 7% on DEA federal registration"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303984014.md"
description: "Trulieve Cannabis rose 7.30% to $11.03 after its medical cannabis business received DEA federal registration."
datetime: "2026-11-02T15:33:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303984014.md)
  - [en](https://longbridge.com/en/news/303984014.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303984014.md)
generator: "portal-rs"
---

# Trulieve Cannabis climbs 7% on DEA federal registration

Trulieve Cannabis (TRLV.US) climbed more than **7%** during regular trading to **$11.03**.

The company announced that its state-licensed medical cannabis business has received federal registration from the U.S. Drug Enforcement Administration (DEA). The registration follows an application submitted after medical cannabis was rescheduled as a Schedule III controlled substance under the Controlled Substances Act. The DEA had previously issued preliminary federal registrations to eligible state-licensed clinics under a new federal framework ordered by the attorney general in April.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [TRLV.US](https://longbridge.com/en/quote/TRLV.US.md)

## Related News & Research

- [Trulieve signs exclusive licensing deal with Connected for Alien Labs, Connected brands in Florida and Texas](https://longbridge.com/en/news/300301416.md)
- [Trulieve highlights 2025 revenue of $1.2 billion in investor presentation](https://longbridge.com/en/news/297783638.md)
- [Oracle Scraps $7B AI Chip Leasing Deal with Tencent Amid U.S. Pressure](https://longbridge.com/en/news/304256419.md)
- [Elon Musk’s Grok Bot is picking up the phone now, and the first calls are wild](https://longbridge.com/en/news/304221156.md)
- [AMD's OpenAI, Meta chip deals trigger $1 billion quarterly charge](https://longbridge.com/en/news/304195048.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**